Literature DB >> 30431083

EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.

Long Chen1, Yongchun Zhou2, Xiaoxia Tang3, Conghui Yang1, Yadong Tian1, Ran Xie1, Ting Chen4, Jiapeng Yang5, Mingwei Jing6, Fukun Chen4, Chun Wang1, Hua Sun1, Yunchao Huang2.   

Abstract

[18F]fluoro‑2‑deoxyglucose (FDG) positron emission tomography (PET)‑computed tomography (CT) is a functional imaging modality based on glucose metabolism. The association between the maximum standardized uptake value (SUVmax) from 18F‑FDG PET‑CT scanning and epidermal growth factor receptor (EGFR) mutation status has, to the best of our knowledge, not previously been fully elucidated, and the potential mechanisms by which EGFR mutations alter FDG uptake are largely unknown. A total of 157 patients who were pathologically diagnosed with non‑small cell lung cancer (NSCLC) who underwent EGFR mutation testing and PET‑CT pretreatment between June 2015 and October 2017 were retrospectively analyzed. χ2 and univariate analyses were performed to identify the contributors to EGFR mutation. The receiver operating characteristic (ROC) curve was analyzed, and the area under the curve (AUC) was calculated. Glucose transporter 1 (GLUT1) and NADPH oxidase 4 (NOX4) expression, and reactive oxygen species (ROS) activity were detected in the A549 (wild‑type), PC‑9 (EGFR mutation‑positive, EGFR exon 19del) and NCI‑H1975 (EGFR mutation‑positive, combined with L858R and T790M substitution) cell lines. A total of 109 patients who met the criteria were enrolled, and 63 of those tested as EGFR mutation‑positive. The SUVmax values were significantly lower in patients with EGFR mutations (mean, 6.52±0.38) compared with in patients with wild‑type EGFR (mean, 9.37±0.31; P<0.001). Using univariate analysis, EGFR mutation status was significantly associated with sex, smoking status, tumor histology and SUVmax of the primary tumor. In the multivariate analysis, smoking status (never‑smoking), histopathology (adenocarcinoma) and SUVmax (≤9.91) were the statistically significant predictors of EGFR mutations. ROC curve analysis identified that the SUVmax cut‑off point was 9.92, for which the AUC was 0.75 (95% confidence interval, 0.68‑0.83). Reverse transcription‑polymerase chain reaction indicated that the GLUT1 mRNA decreased in the PC‑9 and NCI‑H1975 cell lines compared with the A549 cell line (0.82±0.07 and 0.72±0.04 vs. 0.98±0.04, respectively; P<0.05) and decreased ROS activity was observed in the PC‑9 cell line. Furthermore, the expression of NOX4 mRNA decreased by 20% in PC‑9 (P<0.01) and by 14% (P<0.05) in NCI‑H1975 cells. In addition, NOX4 protein expression decreased by 13% in PC‑9 and by 16% in NCI‑H1975 cells (both P<0.05) compared with the A549 cell line. The SUVmax could be considered to effectively predict EGFR mutation status of patients with NSCLC, and the EGFR mutation status may alter FDG uptake partially via the NOX4/ROS/GLUT1 axis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30431083     DOI: 10.3892/ijo.2018.4626

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  16 in total

1.  Predictive value of multiple metabolic and heterogeneity parameters of 18F-FDG PET/CT for EGFR mutations in non-small cell lung cancer.

Authors:  Aiqi Shi; Jianling Wang; Yuzhu Wang; Guorong Guo; Chouchou Fan; Jiangyan Liu
Journal:  Ann Nucl Med       Date:  2022-01-27       Impact factor: 2.668

2.  Predictive value of intratumor metabolic and heterogeneity parameters on [18F]FDG PET/CT for EGFR mutations in patients with lung adenocarcinoma.

Authors:  Ming Ni; Shicun Wang; Xin Liu; Qin Shi; Xingxing Zhu; Yifan Zhang; Qiang Xie; Weifu Lv
Journal:  Jpn J Radiol       Date:  2022-10-11       Impact factor: 2.701

3.  Cold Atmospheric Plasma Boosts Virus Multiplication via EGFR(Tyr1068) Phosphorylation-Mediated Control on Cell Mitophagy.

Authors:  Peiyu Han; Li Shen; Nan Nan; Renwu Zhou; Tianci Li; Xiaofeng Dai
Journal:  Int J Biol Sci       Date:  2022-05-09       Impact factor: 10.750

4.  Diagnostic and Predictive Values of 18F-FDG PET/CT Metabolic Parameters in EGFR-Mutated Advanced Lung Adenocarcinoma.

Authors:  Il Ki Hong; Jeong Mi Lee; In Kyoung Hwang; Seung Sook Paik; Chanwoo Kim; Seung Hyeun Lee
Journal:  Cancer Manag Res       Date:  2020-07-28       Impact factor: 3.989

5.  Increased myocardial 18F-FDG uptake as a marker of Doxorubicin-induced oxidative stress.

Authors:  Matteo Bauckneht; Fabio Pastorino; Patrizia Castellani; Vanessa Cossu; Anna Maria Orengo; Patrizia Piccioli; Laura Emionite; Selene Capitanio; Nikola Yosifov; Silvia Bruno; Edoardo Lazzarini; Mirco Ponzoni; Pietro Ameri; Anna Rubartelli; Silvia Ravera; Silvia Morbelli; Gianmario Sambuceti; Cecilia Marini
Journal:  J Nucl Cardiol       Date:  2019-02-08       Impact factor: 5.952

6.  Correlation between EGFR mutation status and F18 -fluorodeoxyglucose positron emission tomography-computed tomography image features in lung adenocarcinoma.

Authors:  Lei Zhu; Guotao Yin; Wei Chen; Xiaofeng Li; Xiaozhou Yu; Xiang Zhu; Wei Jiang; Chaoyang Jia; Peihe Chen; Yufan Zhang; Di Lu; Lijuan Yu; Xubin Li; Wengui Xu
Journal:  Thorac Cancer       Date:  2019-02-18       Impact factor: 3.500

7.  Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments.

Authors:  Nicolas Borisov; Maxim Sorokin; Victor Tkachev; Andrew Garazha; Anton Buzdin
Journal:  BMC Med Genomics       Date:  2020-09-18       Impact factor: 3.063

8.  Relationship of EGFR Mutation to Glucose Metabolic Activity and Asphericity of Metabolic Tumor Volume in Lung Adenocarcinoma.

Authors:  Wonseok Whi; Seunggyun Ha; Sungwoo Bae; Hongyoon Choi; Jin Chul Paeng; Gi Jeong Cheon; Keon Wook Kang; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2020-06-14

9.  RNA Sequencing in Comparison to Immunohistochemistry for Measuring Cancer Biomarkers in Breast Cancer and Lung Cancer Specimens.

Authors:  Maxim Sorokin; Kirill Ignatev; Elena Poddubskaya; Uliana Vladimirova; Nurshat Gaifullin; Dmitriy Lantsov; Andrew Garazha; Daria Allina; Maria Suntsova; Victoria Barbara; Anton Buzdin
Journal:  Biomedicines       Date:  2020-05-09

10.  RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer.

Authors:  Maxim Sorokin; Elena Poddubskaya; Madina Baranova; Alex Glusker; Lali Kogoniya; Ekaterina Markarova; Daria Allina; Maria Suntsova; Victor Tkachev; Andrew Garazha; Marina Sekacheva; Anton Buzdin
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.